Vedanta Biosciences

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and protection from CDI recurrence Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026. 23 January 2025 -- Massachusetts, US -- Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia...
19 Blackstone Street Cambridge, MA 02139

857-706-1427